Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1
Yun Kang(Progenics Pharmaceuticals (United States)), William C. Olson(Regeneron (United States)), John P. Moore(Cornell University), James Μ. Binley(San Diego Biomedical Research Institute), Michael Franti(Progenics Pharmaceuticals (United States)), Paul J. Maddon(Progenics Pharmaceuticals (United States)), Thomas F. Parsons(Millennium Engineering and Integration (United States)), Sai Prasad N. Iyer(AIL Research (United States)), Antu Dey(International AIDS Vaccine Initiative), Gerald P. Donovan(Progenics Pharmaceuticals (United States)), Kenneth H. Roux(Florida State University), Ping Zhu(Chinese Academy of Sciences), Robert J. Durso(Progenics Pharmaceuticals (United States)), Emma T. Crooks(San Diego Biomedical Research Institute), Sofija Andjelić(Progenics Pharmaceuticals (United States))
Cited by 61
Related Papers
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies
|PLoS Pathogens|2013|1k
Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis
|Science|1990|979
Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer
|Science|2013|826